Oncolytic viruses: programmable tumour hunters

Area of Science:

• Oncology
• Virology
• Biotechnology

Background:

• Cancer remains a leading cause of death, with metastatic disease posing a significant therapeutic challenge.
• Oncolytic viruses are engineered to selectively replicate in and destroy tumor cells by exploiting cancer-specific genetic defects.
• This approach offers a targeted therapy with potential to overcome limitations of conventional treatments.

Purpose of the Study:

• To review the virus:host cell interactions that define the niche for oncolytic viruses.
• To discuss the current and potential clinical applications of oncolytic viruses.
• To examine the limitations and future prospects of oncolytic virotherapy.

Main Methods:

• Review of scientific literature on oncolytic viruses.
• Analysis of virus:host cell interactions in tumor microenvironments.
• Discussion of clinical trial data and preclinical studies.
• Examination of viral families including herpesviruses, adenoviruses, picornaviruses, rhabdoviruses, and paramyxoviruses.

Main Results:

• Oncolytic viruses leverage tumor-specific genetic alterations for selective replication and tumor cell lysis.
• Specific virus-host interactions dictate the efficacy and safety profile of oncolytic virotherapy.
• Herpesvirus, adenovirus, picornavirus, rhabdovirus, and paramyxovirus families are being explored for oncolytic potential.

Conclusions:

• Oncolytic virotherapy represents a promising frontier in cancer treatment, particularly for metastatic disease.
• Understanding virus:host interactions is crucial for optimizing oncolytic virus design and application.
• Further clinical development is needed to fully realize the potential of oncolytic viruses in oncology.